胸腺上皮肿瘤免疫治疗的研究进展  

Research progress in immunotherapy of thymic epithelial tumors

作　　者：何宣露 张琪 苏奕芸 张瑜[2] HE Xuanlu;ZHANG Qi;SU Yiyun;ZHANG Yu(The First Clinical College,Zunyi Medical University,Zunyi,Guizhou 563000,China;Department of Oncology,Guizhou Provincial People’s Hospital,Guiyang,Guizhou 550000,China;Department of Oncology,Tongren People’s Hospital,Tongren,Guizhou 554300,China;School of Medicine,Guizhou University,Guiyang,Guizhou 550000,China)

机构地区：[1]遵义医科大学第一临床学院,贵州遵义563000 [2]贵州省人民医院肿瘤科,贵阳550000 [3]铜仁市人民医院肿瘤科,贵州铜仁554300 [4]贵州大学医学院,贵阳550000

出　　处：《重庆医学》2025年第4期977-982,988,共7页Chongqing Medical Journal

基　　金：贵州省科技计划项目(黔科合平台人才-YQK[2023]021)。

摘　　要：近年来,胸腺上皮肿瘤发病率不断升高,但对于复发转移性胸腺上皮肿瘤患者药物治疗选择却非常有限。免疫检查点抑制剂(ICIs)改变了多种恶性肿瘤的治疗现状,ICIs用于胸腺上皮肿瘤患者亦取得了一定疗效,但相对高发的免疫相关毒副作用(irAEs)限制了其在胸腺上皮肿瘤患者中的广泛应用。该文旨在总结ICIs用于胸腺上皮肿瘤患者的疗效、毒副作用及其相关机制,希望为打破胸腺上皮肿瘤患者免疫治疗困局提供思路。A rising frequency of thymic epithelial tumors has been noted recent years,however limited drugs can be chosen for recurrent and metastatic thymic epithelial tumors patients.Treatment patterns in multiple tumors have been rapidly developing in parallel with the growing use of immune checkpoint inhibitors(ICIs).Although ICIs have showed certain efficacy in thymic epithelial tumors patients,the relatively high incidence of immune-related adverse events(irAEs)limited its application.This review aims to summary the efficacy,side effects and related mechanisms of ICIs for treating thymic epithelial tumors patient,which may shed light on the predicament of immunotherapy for thymic epithelial tumors patients.

关 键 词：胸腺上皮肿瘤 免疫检查点抑制剂 免疫相关毒副作用 胸腺 免疫治疗 

分 类 号：R736.3[医药卫生—肿瘤]